2 results
Approved WMOCompleted
Part 1: To assess the safety and effectiveness of subcutaneous golimumab 50 mg (SC-GLM50), administered by autoinjection once monthly during 6 months, when combined with different DMARD regimens used in daily rheumatology. Part 2: In subjects who…
Approved WMOCompleted
The proposed experimental pilot study focuses on harm reduction in a specific subpopulation, i.e. in patients with schizophrenia (long-term psychotic disorder) with a suboptimal response to the currently available interventions, smoking a lot of…